• ProMIS Neurosciences (PMN) will present data supporting the company’s Alzheimer’s Disease program at the Tau2020 Global Conference.
  • The presentation will discuss the company’s antibody candidates, and their use in future therapy and treatment for Alzheimer’s.
  • ProMIS’s drug discovery and development platform shows potential for improving the success and speed of current drug development attempts.
  • The Tau2020 Global Conference will be held on February 12th and 13th, at the Marriott Marquis Hotel in Washington D.C.
  • ProMIS’ share price is up 4.76 per cent, with shares trading at $0.22 apiece.

Biotechnology company ProMIS Neurosciences (PMN) will present data which supports their Alzheimer’s Disease program at the Tau2020 Global Conference.

The event will be hosted at the Marriott Marquis Hotel in Washington D.C., on February 12th and 13th.

The international conference will bring together academics, industry leaders, sponsors, and scientists from around the world. They will share and discuss the latest advances in tau research and neurodegenerative issues.

ProMIS’s Chief Development Officer, Dr Johanne Kaplan, will present data at the conference, and discuss the company’s program to target neurotoxic tau.

Dr Kaplan will also demonstrate the antibody candidates’ abilities, which were produced using ProMIS’s drug discovery and development platform.

The antibodies, which can bind and neutralise the seeding activity of toxic tau species, show great potential for use in future Alzheimer’s therapy and treatment.

ProMIS’s drug discovery and development platform has already produced high-quality, precisely selective antibody candidates.

Dr Kaplan commented, “We created ProMIS to discover and advance new antibody candidates that can selectively target the toxic forms of misfolded proteins, including amyloid and tau, for potential therapies for a range of neurodegenerative diseases.”

“We’re pleased to share our findings for tau with the larger community and to have our data recognised by such an accomplished program committee.”

ProMIS’ share price is up 4.76 per cent, with shares trading at $0.22 apiece.

More From The Market Online

Buzz on the Bullboards: Where volatility meets opportunity

Some indices hit lows not seen in nearly a year after a concerning inflation report, only to bounce back the next day.

Telo Genomics kick-starts clinical trial for multiple myeloma patients

Telo Genomics has kick-started its clinical trial for multiple myeloma patients after receiving the first patient sample from the trial.

Theralase donates laser therapy tech to help research Parkinson’s treatment

Theralase Technologies (TSXV:TLT) has donated some of its technology to help advance university studies into Parkinson’s Disease treatment.

BioNxt reveals results from multiple sclerosis treatment study

BioNxt Solutions (CSE:BNXT) is one step closer to having its proprietary Cladribine product available to treat multiple sclerosis.